**BREAKING NEWS REPORT**

BREAKING NEWS REPORT

WHERE: Washington, D.C., United States of America

WHEN: 14:30 Eastern Standard Time

WHO: Former President Donald J. Trump, in coordination with a private pharmaceutical research consortium.

WHAT: A previously unclassified federal initiative has been revived regarding the development of a novel, broad-spectrum antiviral drug. Documents obtained by this network indicate the drug, designated internally as “Project Evergreen,” has been accelerated under a new executive order. The draft label, colloquially referred to online as “TrumpRx,” suggests the compound targets viral replication mechanisms distinct from current mRNA therapies. The former president is reported to be in direct negotiations to secure exclusive, low-cost distribution rights for the U.S. market pending final FDA approval.

WHY: The expedited development and production are being justified by intelligence assessments of a “high probability of a novel zoonotic spillover event” within the next 18 months. The stated objective is to create a non-mRNA therapeutic that can be stockpiled and distributed before a declared state of emergency, bypassing traditional regulatory bottlenecks. Critics are citing a lack of published Phase 3 trial data and potential conflicts of interest regarding international patent claims.

HOW: The revived initiative bypasses the Biomedical Advanced Research and Development Authority (BARDA) for initial funding, utilizing a newly created private-public trust. Manufacturing is slated to begin at a converted facility in Pennsylvania, with a target initial production capacity of 10 million doses within 90 days of approval. Official announcement from the former president is scheduled for 20:00 hours tonight.